Profiling of FDA-Approved and Clinical Trial Drugs Revealed Shared Cytotoxicity And Collateral Sensitivity In Resistant (H69ar) And Non-Resistant (H69) Small Cell Lung Cancer Cells. (Drug Repurposing in Cancer Chemotherapy) by Agyemang, Pius Reyderg
South Dakota State University 
Open PRAIRIE: Open Public Research Access Institutional 
Repository and Information Exchange 
Electronic Theses and Dissertations 
2021 
Profiling Of FDA-Approved and Clinical Trial Drugs Revealed 
Shared Cytotoxicity And Collateral Sensitivity In Resistant (H69ar) 
And Non-Resistant (H69) Small Cell Lung Cancer Cells. (Drug 
Repurposing in Cancer Chemotherapy) 
Pius Reyderg Agyemang 
Follow this and additional works at: https://openprairie.sdstate.edu/etd2 
 Part of the Biochemistry Commons 
PROFILING OF FDA-APPROVED AND CLINICAL TRIAL DRUGS REVEALED 
SHARED CYTOTOXICITY AND COLLATERAL SENSITIVITY IN RESISTANT 
(H69AR) AND NON-RESISTANT (H69) SMALL CELL LUNG CANCER CELLS. 
(DRUG REPURPOSING IN CANCER CHEMOTHERAPY) 
BY 
PIUS REYDERG AGYEMANG 
A dissertation submitted in partial fulfillment of the requirements for the 
Doctor of Philosophy 
Major in Biochemistry 
South Dakota State University 
2021 
ii 
DISSERTATION ACCEPTANCE PAGE 
This dissertation is approved as a creditable and independent investigation by a candidate 
for the Doctor of Philosophy degree and is acceptable for meeting the dissertation 
requirements for this degree.  Acceptance of this does not imply that the conclusions 
reached by the candidate are necessarily the conclusions of the major department. 
 Advisor Date 
Department Head   Date 
Nicole Lounsbery, PhD  





©2021 by Pius Reyderg Agyemang 
























My first intense gratitude goes to Almighty God in whom I have believed to have 
made this possible through thick and thin. And to the Department of Chemistry and 
Biochemistry for giving me the opportunity and resources to achieve this. Sincere gratitude 
goes to my supervisor Dr. Rachel Willand-Charnley for her guide and wonderful leadership 
role. She opened her door and welcomed me at the latter part when things seemed tough. I 
am grateful for her cordiality. 
I would also like to thank my former supervisor Dr. Iram Surtaj for believing in me 
and making me realize my potential. His effort is much appreciated. I also thank my 
committee members: Dr. Halaweish Fathi, Dr. Thomas Brandenburger and Dr. Raynie 
Douglas for their wonderful guide and constructive criticism which has put me on my toes 
to become a better researcher and a critical thinker. I am very grateful to you all for your 
effort. 
And to my family back home who have been supporting and encouraging me, I say 
a big thank you to all of you especially my mother Theresah Pomaah whom I dedicate this 
certificate to, and to my father, Peter Danso whose advice I have heeded to. Together we 
made this. 
My second gratitude goes to my lab mates Jennifer, Vivian, Angie, Mathias, Albert, 
and Isaac for their contributions one way or the other to this project, especially Jennifer, 
Mathias and Vivian who will make time off their busy schedules for me when I needed it. 




My last gratitude is for the wonderful woman in my life who has been and still 
pushing me beyond my limit. She will always say “try again”, and yes, the several trials 
paid off. I really appreciate her.  


















TABLE OF CONTENTS 
ABBREVIATIONS……………………………………………………………………... x 
LIST OF FIGURES……………………………………………………………………... xii 
LIST OF TABLES………………………………………………………………………xiii 
ABSTRACT……………………………………………………………………………. xiv 
CHAPTER 1…………………………………………………………………………….  1 
1.1. Background…………………………………………………………..……... 1 
CHAPTER 2…………………………………………………………………………….  7 
 2.1. Introduction………………………………………………………………… 7 
 2.2. Materials and Methods……………………………………………………... 8 
  2.2.1. Chemicals………………………………………………………… 8 
  2.2.2. Cell lines and cell culture………………………………………… 8 
  2.2.3. Cytotoxicity assay………………………………………………... 8 
 2.3. Results and Discussion……………………………………………………... 9 
  2.3.1. Phenotype A - Resistance………………………………………… 9 
  2.3.2. Phenotype B - Shared Cytotoxicity……………………………… 12 




CHAPTER 3……………………………………………………………………………. 24 
 3.1. Introduction………………………………………………………………… 24 
 3.2. Apoptosis Assay……………………………………………………………. 26 
  3.2.1. Materials and Methods…………………………………………… 26 
   3.2.1.1. Chemicals………………………………………………. 26 
   3.2.1.2. Cell lines and cell culture………………………………. 26 
   3.2.1.3. Annexin V/7-AAD apoptosis assay…………………….. 26 
 3.3. Results and Discussion……………………………………………………... 27 
CHAPTER 4…………………………………………………………………………….. 33 
 4.1. Introduction………………………………………………………………… 33 
 4.2. MRP1 dependent collateral sensitivity assay………………………………. 37 
  4.2.1. Materials and Methods…………………………………………..... 37 
   4.2.1.1. Chemicals………………………………………………. 37 
   4.2.1.2. Cell lines and cell culture……………………………….. 37 
   4.2.1.3. Cytotoxicity assay………………………………………. 38 
 4.3. Results and Discussion………………………………………………………38 
 4.4. Caspase dependent collateral sensitivity assay……………………………... 40 
  4.4.1. Materials and Methods……………………………………………. 40 
ix 
 
   4.4.1.1. Chemicals………………………………………………. 40 
   4.4.1.2. Cell lines and cell culture………………………………. 41 
   4.4.1.3. Cytotoxicity assay……………………………………… 41 
 4.5. Results and Discussion…………………………………………………….. 42 
 4.6. Total Thiol (glutathione) depletion………………………………………… 45 
  4.6.1. Materials and Methods…………………………………………… 45 
   4.6.1.1. Chemicals………………………………………………. 45 
   4.6.1.2. Cell lines and cell culture………………………………. 45 
   4.6.1.3. Thiol depletion assay…………………………………… 45 
 4.7.  Results and Discussion…………………………………………………….. 47 
CHAPTER 5…………………………………………………………………………….. 49 
 5.1. Summary………………………………………………………………….... 49 
 5.2. Conclusions………………………………………………………………… 50 
 5.3. Recommendations………………………………………………………….. 52 







7-AAD                 7-aminoactinomycin D 
ABC                    ATP Binding Cassette 
ALK                     Anaplastic Lymphoma Kinase. 
Apaf1                   Apoptosis Activating Factor 1. 
Bak                       B-cell lymphoma associated protein K. 
BSO                      L-Buthionine Sulfoximine 
Caspase                Cysteine-dependent Aspartate-directed Proteases. 
CS                        Collateral Sensitivity 
DISC                    Death inducing Signaling Complex. 
DMSO                 Dimethyl Sulfoxide. 
E217βG                Estradiol Glucuronide 
Erl                        Erlotinib 
EGFR                   Epidermal Growth Factor Receptor. 
FADD                  Fas-associated Death Domain 
FGFR1                 Fibroblast Growth Factor Receptor 1 gene. 
Flud                      Fludarabine phosphate 
GPX4                  Glutathione Peroxidase 4 
GSH                    Glutathione 
GST                     Glutathione S Transferase 
KRAS                  Kirsten Rat Sarcoma gene. 
LTC4                    Cysteinyl Leukotriene 
MET                    Mesenchymal Epithelial Transition factor gene. 
MOMP                Mitochondrial Outer Membrane Permeabilization 
MRP1                  Multi-drug Resistance Protein 1 
MYC                   Myelocystomatosis 
NAC                    N-acetylcysteine 
NBD                    Nucleotide Binding Domains 
xi 
 
NSCLC                Non-Small Cell Lung Cancer Cell. 
pRb                      Retinoblastoma 
PTPM1                Protein Tyrosine Phosphate Mitochondrial 1 
Pyri                      Pyrimethamine 
ROS                     Reactive Oxygen Species 
SCLC                   Small Cell Lung Cancer Cell. 




LIST OF FIGURES 
Figure 1. The various types of lung cancer and their associated proto-oncogenes ……… 1 
Figure 2. The orientation and topology of MRP1 ……………………………………...... 4 
Figure 3. Cell viability of SCLC cells showing resistance in H69AR …………………. 11 
Figure 4. Chemical structure of phenotype B drugs ……………………………………. 12 
Figure 5. Cell viability of SCLC cells showing shared cytotoxicity ………….…….….. 13 
Figure 6. Dose-dependent cytotoxicity on SCLC cells ……………………….……….... 16 
Figure 7. Chemical structure of phenotype C drugs …………………………………….. 21 
Figure 8. Cell viability of SCLC cells showing collateral sensitivity in H69AR ……….. 22 
Figure 9. Dose dependent cytotoxicity of collateral sensitivity drugs on SCLC cells ….. 23 
Figure 10. Flow cytometric analysis of Alexidine HCl ………………..……………….. 30 
Figure 11. Flow cytometric analysis of Ouabain ..……………………………………… 31 
Figure 12. Flow cytometric analysis of Cetrimonium bromide ………………………… 32 
Figure 13. Putative mechanism of collateral sensitivity………………..……………..… 35 
Figure 14. Cell viability of H69AR cells showing the effect of inhibiting MRP1………. 40 
Figure 15. Inhibitory effect of a caspase inhibitor ………………………..…………….. 42 
Figure 16. Cell viability of H69AR cells showing the effect of inhibiting pan caspase… 44 
Figure 17. SN2 displacement of bromide ions on dibromobimane ……………………… 46 






LIST OF TABLES 
Table 1. Phenotype A drugs descriptions ………………………………………………... 11 
Table 2. Phenotype B drugs descriptions and their IC50 values for H69 and H69AR ….. 16 




















PROFILING OF FDA-APPROVED AND CLINICAL TRIAL DRUGS REVEALED 
SHARED CYTOTOXICITY AND COLLATERAL SENSITIVITY IN RESISTANT 
(H69AR) AND NON-RESISTANT (H69) SMALL CELL LUNG CANCER CELLS. 
(DRUG REPURPOSING IN CANCER CHEMOTHERAPY) 
PIUS REYDERG AGYEMANG 
2021 
 
Some cancers are capable of “spitting out” drugs being fed to them, metaphorically 
speaking, becoming resistant to what were previously effective chemotherapeutics. In 
small-cell lung cancer (SCLC), an overexpression of a membrane protein (MRP1) and its 
transport activity can lead to chemotherapy failure. However, this study showed that certain 
drugs are selectively cytotoxic (exhibit collateral sensitivity) to MRP1-overexpressed 
SCLC (H69AR) cells. In this study, three drugs (Erlotinib, Pyrimethamine, Fludarabine) 
were identified to exhibit a dose-dependent collateral sensitivity on H69AR with IC50 
values of ~3.5 µM, ~2 µM, and ~20 µM respectively. Halting the transport activity of the 
MRP1 with 25 μM MK-571 or 5 μM reversan increased the percent cell viability of MRP1 
cells that were treated with erlotinib and pyrimethamine. Thus, the collateral sensitivity 
induction by these drugs disappeared. Also, the collateral sensitivities of erlotinib and 
azd1480 were shown to depend on caspase (P < 0.005) when the pan caspase inhibitor (Q-
VD-OPh) was used to inhibit caspase activation. In a GSH-depletion fluorescence assay 
using 40uM dibromobimane, the collateral sensitivities of erlotinib and azd1480 again 
xv 
 
were shown to deplete total thiols (GSH) when 30uM of the drug is added to cells that have 
been treated with 50 μM N-acetylcysteine (NAC) for 48hrs. In another experiment, three 
non-oncology drugs were identified to exhibit shared cytotoxicity on both H69 and 
H69AR. Using MTT cytotoxicity assay, alexidine HCl, ouabain and cetrimonium bromide 
(the three non-oncology drugs) induced a shared cytotoxicity on both H69 and H69AR 
with ic50 of ~1 µM, ~8 nM, and ~1 µM, respectively. Employing annexin V apoptosis 
assay, alexidine HCl, and cetrimonium bromide induced apoptosis in both H69 and 
H69AR. Ouabain on the other hand was necrotic on H69 but induced apoptosis in H69AR. 
These investigations unveiled the cytotoxic mechanisms and targets that could lead to a 
possible way to accelerate the development of new cancer drugs or repurpose an existing 














Lung cancer is the leading cause of cancer-related death, part of the reason being 
their ability to remain alive through certain adaptations which has led to poor prognosis. 
Each year, more people die of lung cancer than colon, prostate, and breast cancer combined. 
Thus, lung cancer accounts for 13.2% of all new cancers and 25.9% of all cancer death 
(Cancer Stat Facts, n.d.; Siegel et al., 2021). The overall five-year survival rate of lung 
cancer is lowest compared to most other cancers (Cancer Stat Facts, n.d.; Siegel et al., 
2021). In many cases, cancer-causing substances in the air are inhaled and cause cell 
damage that later becomes cancer. The various types of lung cancers can be classified as 
either being a small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). 
NSCLC constitutes about 85% of all lung cancer cases but it is less aggressive as compared 
to SCLC which constitutes about 15% of lung cases (Cancer Stat Facts, n.d.; Siegel et al., 
2021). The various types of lung cancers are shown in Figure 1. 
 
Figure 1. The various types of lung cancer and their associated proto-oncogenes. 
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Certain genetic changes have been associated with lung cancer. A mutation or gene 
amplification which leads to an activation of a proto-oncogene, or deactivation of tumor 
suppressor gene, may lead to cancer. Proto-oncogenes are normal genes which help in cell 
growth and development by producing growth factors, growth-factor receptors, 
transcription factors and signal transduction proteins. Proto-oncogenes associated with 
lung cancer includes Kirsten rat sarcoma gene (KRAS), mesenchymal epithelial transition 
factor gene (MET), epidermal growth factor receptor gene (EGFR), anaplastic lymphoma 
kinase gene (ALK), fibroblast growth factor receptor 1 gene (FGFR1), and 
myelocystomatosis gene (MYC) (Antoniou et al., 2013). Tumor-suppressor genes are 
genes responsible for preventing the excessive growth of cells. Tumor-suppressor genes 
act as gate keepers, which directly suppress growth, or care takers, which maintain the 
overall genetic stability of the cells. Tumor-suppressor genes associated with lung cancer 
include tumor protein gene (TP53) and retinoblastoma gene (pRb) (Kumar et al., 2014). 
Although abnormal functioning of these genes has been associated with lung cancer, 
certain risk factors like smoking and pollution have been shown to play a part in causing 
cells to become cancerous. These risk factors can cause genetic changes in both small cells 
and non-small cells of the lungs, leading to uncontrolled growth of cells and hence tumor 
formation. Tumors of lung cancer could start from cells lining the bronchi, bronchioles, or 
alveoli of the lungs and spread through one side of the chest, which is referred to as the 
limited stage, or the whole chest and other parts of the body, which is referred to as the 
extensive stage (American Cancer Society [ACS], n.d). The SCLC type of lung cancer 
spreads (metastasize) relatively faster, and for this reason, about 70% of people with SCLC 
will have lung cancer that has already spread at the time they are diagnosed (American 
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Cancer Society [ACS], n.d.). In terms of treatment, SCLC responds very well to 
chemotherapy than any other form of therapy due to its high rate of metastasis. (American 
Cancer Society [ACS], n.d.) 
Chemotherapy in cancer treatment is where an anti-cancer drug may be injected 
into a vein or taken by mouth. These drugs travel through the bloodstream and reach most 
parts of the body. For limited stage SCLC, chemotherapy is often given at the same time 
with radiation therapy (this is the use of high energy rays to kill cancer cells). This is termed 
as concurrent chemoradiation (American Cancer Society [ACS], n.d.). Drugs that are 
commonly used to treat SCLC are cisplatin and carboplatin. Either of these drugs is given 
with etoposide or irinotecan in a combinatorial regimen (American Cancer Society [ACS], 
n.d.). Cisplatin causes ferroptosis (a type of programmed cell death that is dependent on 
iron by inhibiting glutathione peroxidase 4 (GPX4) protein which is responsible for 
reducing cytotoxic lipid peroxide (a marker of ferroptosis) to corresponding alcohols 
(Siddik, 2003). Etoposide and irinotecan inhibit topoisomerases (enzymes involved in 
DNA replication) and hence interfering with DNA synthesis (Beauchesne et al., 1997). 
Although chemotherapy is by extension the most effective treatment form of SCLC, certain 
adaptations of some cancer cells have led to chemoresistance which accounts for about 90 
percent of chemotherapy failure. Mutation of drug receptors or transporters, mutation of 
target sites of drugs, and enhanced drug efflux caused by increased expression of ATP 
binding cassettes (ABC) membrane transporters such as P-glycoprotein (P-gp/ABCB1), 
multi-drug resistance protein (MRP/ABCC1) 1 and breast cancer resistance protein 
(BCRP/ABCG2) have been associated with chemoresistance in cancer cells. These ABC 
membrane transporters have been involved in multi-drug resistance (MDR) which accounts 
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for about 90 percent of chemotherapy failure. Long exposure of doxorubicin (a 
conventional oncology drug) and its related anthracycline compounds to H69 (a small cell 
lung cancer cell line) causes these cells to overexpress multi-drug resistance protein (MRP) 
1 responsible for their chemoresistance (Cole et al., 1992) 
Bioinformatic analysis of the open reading frame of MRP1 mRNA suggests its 
membership in the ATP Binding Cassette (ABC) superfamily transmembrane transporters 
with MRP polypeptide weighing approximately 171kDa when it is not modified 
(Ambudkar et al., 1999). Like many vertebrates, members of the ABC superfamily MRP 
contain two nucleotide binding domains (NBDs), each preceded by multi-spanning 
transmembrane region (TMD) as shown in Figure 2.  
 
 
Figure 2. The orientation and topology of MRP1. Lu, Pokharel, and Bebawy (2015). 
 
The NBDs are involved in ATP hydrolysis during transport of substances out of the 
cell. In the human body, MRP1 is primarily expressed in the basolateral membrane of 
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epithelial cells of organs such as the lung, gastrointestinal tract, kidney, pancreas, testis, 
placenta, bladder, and adrenal gland (Flens et al., 1996). MRP1 governs the absorption and 
disposition of a wide variety of endogenous and exogenous substrates across organs, 
serving as physiological barriers in the nervous cells and protecting tissues from toxic 
molecules (Schinkel et al., 2003; Chen et al., 2016). MRP1 can also transport organic 
anions such as cysteinyl leukotriene (LTC4), estradiol glucuronide (E217βG), glutathione 
(GSH), and cobalamin (Leier et al., 1996; Jedlitschky et al., 1996; Beedholm-Ebsen et al., 
2010), which happen to be its physiological substrates. MRP1 effluxes conventional 
cytotoxic anti-cancer agents such as doxorubicin, etoposide, vincristine, and methotrexate 
(Cole, 2014). MRP1 can also affect the bioavailability of various types of antivirals, 
antimalarials, and antibiotics (Cole, 2014). This ability of the MRP1 to develop cross 
resistance for other compounds makes it a key player of multi-drug resistance. Multi-drug 
resistance (MDR) be it inherent or acquired is inevitable, and it is characterized by the 
simultaneous resistance to drugs that differ both structurally and mechanistically. 
Apart from the resistance from cancer cells which leads to chemotherapy failure, 
there are other factors like time and money spent on manufacturing of novel oncology 
drugs and afflictive side effects of many oncology drugs, which tend to dawdle 
chemotherapy. These problems in chemotherapy are what this project is intended to 
provide solutions to. Among many of the solutions is drug repurposing, where an FDA-
approved or clinical trial drug is used as a viable alternative in the treatment of a particular 
disease. In recent years, drug repurposing in chemotherapy has gained popularity as a 
strategy to accelerate the development of a new cancer drug. Researchers have discovered 
that drugs used for treating diabetes, alcoholism and arthritis can also kill cancer cells in 
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the lab (Corsello et al., 2020). A typical example of a drug that has been repurposed for 
chemotherapy is disulfiram which was originally designed for the treatment of chronic 
alcoholism. This drug was later reported to inhibit proteasome in some cancer cells leading 
to their death (Lövborg et al., 2006; Chen et al., 2006). Because these FDA-approved drugs 
have already been assessed for safety and efficacy, there is low risk of failure and low 
overall cost from bench to bedside than if a new drug is being tested. As a solution to 
chemoresistance, drug repurposing can provide a safe alternative for the treatment of 
cancer cells that have accrued genetic alterations leading to the resistance to what were 
previously effective chemotherapeutics. This work will therefore achieve the drug re-
purposing purpose through three aims:  
1. Investigate the anticancer properties of selected FDA-approved and clinical trial 
drugs on both resistant (H69AR) and non-resistant (H69) small cell lung cancer 
(SCLC) cells. 
2. Investigate the cytotoxic mechanism of non-oncology drugs on both H69 and 
H69AR. 










INVESTIGATING THE ANTICANCER PROPERTIES OF SELECTED FDA-
APPROVED AND CLINICAL TRIAL DRUGS ON BOTH RESISTANT (H69AR) AND 
NON-RESISTANT (H69) SMALL CELL LUNG CANCER (SCLC) Cells. 
 
2.1. Introduction 
In most cancer cells, either an oncogene is activated, or a tumor suppressor gene is 
deactivated, causing cells to grow uncontrollably leading to tumor formation. Cell growth 
and division start with replication of DNA and synthesis of organelles. Several pathways 
that lead to growth and division of cells have been exploited by chemotherapeutics to kill 
cancer cells. These include, but is not limited to, targeting key enzymes such as aurora 
kinase in cell division, topoisomerase or telomerase in DNA replication, proteosome, 
glutathione peroxidase 4, and cytoskeletons like microtubules which aid in mitosis. Suffice 
it to say that a drug which can inhibit any of the key pathways mentioned above could be 
cytotoxic to cancer cells.  
In this investigation, 118 FDA- approved and clinical trial drugs were screened for 
their cytotoxicity on H69 and H69AR cells. Some of which were oncology drugs and are 






2.2. Materials and Methods 
2.2.1. Chemicals 
FDA-approved and clinical trial drugs were procured from Selleckchem (Houston, 
TX), dimethyl sulfoxide (DMSO), thiazolyl blue tetrazolium bromide (MTT) and sodium 
dodecyl sulfate were procured from Sigma-Aldrich (St. Louis, MO). 
2.2.2. Cell lines and cell culture 
H69 and H69AR cells were procured from ATCC (Manassas, VA). H69 and 
H69AR cell lines were cultured in RPMI 1640 (ATCC) media supplemented with 10% 
fetal bovine serum. H69AR cells were challenged monthly with 0.8 µM doxorubicin and 
cultured drug-free for one week before use. Cells were grown in a humidified incubator 
maintaining 5% CO2 at 37 °C. 
2.2.3. Cytotoxicity assay 
Cell sensitivity to drugs was analyzed using the MTT colorimetric assay. 250,000 
cells in 100 μL RPMI 1640 media are seeded in a 96-well plate (CellBIND®, Corning). 
Plates are incubated at 37oC for 24hrs. The next day, cells were treated with 15 μM drugs 
and incubated for 96 hours. DMSO concentration was maintained at 0.15% as a negative 
control. In a dose-dependent cytotoxicity test, a serial dilution by half was done to obtain 
eight different concentrations, usually the highest concentration is 50 μM and the lowest is 
0.391 μM. DMSO concentration is maintained at 0.5% for all eight concentrations. At the 
end of the incubation period, 100 µL of culture medium was carefully removed and cells 
were treated with 0.5 mg/mL of MTT dye (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) for 4hrs. The formazan crystals were dissolved by the 
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addition of 120 µL 15% SDS containing 0.01%v/v HCl and absorbance at 570 nm was 
recorded using a Hidex Sense Beta Plus plate reader (Turku, Finland).  
 
2.3. Results and Discussion 
The MTT dye was reduced to insoluble formazan crystals by NAD(P)H-dependent 
oxidoreductase enzymes present in viable cells. The formazan crystals were dissolved 
using solubilization solution as described in the method. At wavelength of 570 nm, the 
dissolved formazan crystals have maximum absorbance which give an optical density (OD) 
value that corresponds to the number of viable cells. The higher the OD value the higher 
the number of viable cells and vice versa. The OD values of the drugs were normalized 
with that of 0.15% DMSO and expressed as percentage as shown below. This 
normalization was done because the drugs contain 0.15% of DMSO as solvent. 
  Percent cell viability = 
OD of drug
OD of 0.15% DMSO
 x 100 
After the initial screening, drugs were categorized into three phenotypes based on 
their relative cytotoxicity on H69 and H69AR. These phenotypes are Phenotype A 
(Resistance), Phenotype B (Shared cytotoxicity) and Phenotype C (Collateral Sensitivity).  
 
2.3.1. Phenotype A – Resistance 
            Drugs in this phenotype exhibited selective cytotoxicity towards the parental cell 
(H69) with little or no effect on the resistant cells (H69AR) hence the phenotype name 
resistance. These drugs are trifluridine (antiviral), defarasirox (iron chelating agent), 
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vinblastine (oncology drug), dipyridamole (platelet inhibitor), JNK-IN-8 (oncology), and 
chloroxine (antibacterial) listed in table 1. As shown in Figure 3, there is a large difference 
in percent cell viability (with p < 0.05) between H69 and H69AR for all the six drugs. The 
0.15% DMSO which was set as a control did not show toxicity on both cells. H69AR cells 
showed relatively high resistance in JNK-IN-8 and chloroxine with percent cell viability 
greater than 100. On the other hand, H69 was very sensitive to JNK-IN-8 and chloroxine 
with relatively low percent cell viability. According to Susan and Cole (2014), MRP1 can 
affect the bioavailability of antiviral and antibacterial drugs due to the resistance towards 
these drugs. In this work, it was also shown that MRP1-overexpressed cells (H69AR) are 
resistant to different classes of drugs including the oncology drugs, iron chelating agents, 
antiviral, antibacterial and platelet inhibitors, this evident the multi-drug resistance of 
MRP1. Iron chelating agents are useful in inhibiting ferroptosis (a kind of programmed cell 
death induced by iron), and platelet inhibitors are useful in conditions where there is an 
excessive blood clotting. The resistance of the MRP1-overexpressed cells demonstrated in 
this work towards these drugs is also an advisory notice that the drugs cannot be used to 
achieve their functions in cells that overexpress MRP1.  
The rest of the work focused on the other two phenotypes which were part of the 
underpinning goals of this project, thus drug repurposing in chemotherapy, hence no 
further experiment was performed with drugs in the phenotype A. However, the results 
from this phenotype complete and validate the ideologies of the other two phenotypes 




Figure 3. Viability of SCLC cells showing resistance in H69AR on exposure to 15 μM 
drugs for 96 hrs. Viability was assessed by MTT assay and drug effect was normalized with 
0.15% DMSO. Error bars represent standard errors of the mean of two experiment each 
done in triplicate. *S denotes cell viability of H69AR significantly different from H69 with 







2.3.2. Phenotype B – Shared Cytotoxicity. 
The term shared cytotoxicity was used to describe drugs in this phenotype because 
of their ability to kill greater number (about 80 percent) of both H69 and H69AR with 
minimal or no significant difference between the percent cell viabilities of the two cell 
lines. Three non-oncology drugs namely alexidine HCl, ouabain and cetrimonium bromide 
were found to exhibit shared cytotoxicity. The bar graph from the initial screening is shown 
in Figure 5, and in this Figure, the percent cell viabilities of both H69 and H69AR for all 
the drugs are below 20 which demonstrate their shared cytotoxicity. The first drug in this 
category is alexidine HCl which is an alkyl bisbiguanide (Figure 4). Bisbiguanides are 
known for their bactericidal properties and alexidine HCl has been found to have 
antimicrobial functions and it is used in mouthwash (Zorko & Jerala, 2008). This non-
oncology drug has also been found to inhibit the mitochondrial phosphatase PTPMT1 and 
induces apoptosis in some cancer cell lines (Doughty-Shenton et al., 2010).  




Figure 5. Viability of H69 and H69AR cells on exposure to 15 μM drugs for 96hrs. Viability 
was assessed by MTT assay and drug effect was normalized with 0.15% DMSO. Error bars 
represent standard errors of the mean of two experiments done in triplicate. 
 
Exposing both cell lines to 15 µM of alexidine HCl (S4302) for 96 hours, the drug 
exhibited a shared cytotoxicity with percent cell viabilities less than 10 on both cell lines 
as seen in Figure 5. In a dose-dependent cytotoxicity test, where varying concentrations of 
a drug were used instead of a single concentration, it was found that the cytotoxicity of 
alexidine HCl on both H69 and H69AR is dose dependent as shown in Figure 6 (a), with 
half maximal inhibitory concentration (IC50) value of ~1 μM each for both H69 and 
H69AR. Dose-dependent test is usually employed in cytotoxicity tests to find out whether 
the effect of a drug depends on how much given, and also to determine the half maximal 
inhibitory concentration (IC50). IC50 in this experiment is defined as the concentration of 
drug that kills half of the cells. It is also a measure of the potency of the drugs in killing 
the cells. The low IC50 values for both cell lines indicate that alexidine HCl is very potent 
in killing the small-cell lung cancer cells. Also, the relative cytotoxicity of alexidine HCl 
on both cell lines can be deduced from the steepness or the positions of the sigmoidal curves 
14 
 
of the H69 and H69AR relative to each other. At very low concentrations of alexidine HCl, 
the sigmoidal curve of H69AR lies below that of the H69 and significant differences are 
seen in the percent cell viabilities of the H69 and H69AR, thus the drug kills more H69AR 
cells than H69. As the concentration increases near the IC50, the extent of cytotoxicity 
becomes almost equal for both cell lines hence the shared cytotoxicity. 
The second drug in this phenotype is ouabain, a cardiac glycoside which consist of 
a sugar molecule bound to a modified cholesterol by a glycosidic linkage (Figure 4). 
Ouabain is toxic to cells because it can inhibit sodium potassium pump which is found in 
the plasma membrane of almost every human cell and causes depolarization of neurons 
leading to osmolysis or calcium necrosis in brain tissues (Wang et al., 2004). However, at 
lower concentrations, ouabain can be used medically to treat hypotension and arrhythmias 
(Wang et al., 2004). In this work, the shared cytotoxicity of 15 µM ouabain (S4016) on 
both cell lines was demonstrated and shown in Figure 5. The dose-dependent cytotoxicity 
test of the drug on both cell lines was also shown in Figure 6(b), with an IC50 value of 7.9 
nM for H69 and 9.1 nM for H69AR. These low IC50 values inform the high potency of this 
drug on both cell lines. The sigmoidal curve of H69 lies below that of the H69AR indicating 
that although the drug is toxic to both cell lines, it kills more H69 than H69AR at all 
concentrations, especially the lower concentrations. As the concentration increases pass 32 
nM, the gap between the two curves narrows, which means that the drug at higher 
concentrations exhibits similar potency on both cell lines. This low concentration of 
ouabain can be considered medically to treat small cell lung cancer with minimal or no 
effect on normal cells.  
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The third non-oncology drug in this phenotype is cetrimonium bromide, an amine 
based cationic quaternary surfactant (Figure 4). The hexadecyltrimethylammonium cation 
is an effective antiseptic agent against bacteria and fungi. Some topical antiseptics 
including cetrimonium bromide have been shown to have effect on cancer cells in vitro 
(Sopata et al., 2008). Cetrimonium bromide exhibits anticancer cytotoxicity against several 
HNC (head and neck cancer) cell lines with minimal effects on normal fibroblasts, a 
selectivity that exploits cancer-specific metabolic aberrations (Ito et al., 2009). In this 
work, cetrimonium bromide also exhibited cytotoxicity on small cell lung cancer cell lines, 
the H69 and its resistant H69AR. At 15 µM of the drug, a shared cytotoxicity was seen on 
both cell lines as shown in Figure 5. Also, the dose-dependent cytotoxicity of this drug was 
demonstrated on H69 and H69AR cells with IC50 values of 1.1 μM and 2 μM, respectively 
as shown in Figure 6 (c). At very low concentrations, the sigmoidal curve of the H69AR 
falls below that of the H69, an indication of higher sensitivity exhibited by the H69AR 
towards the drugs at these concentrations. After about 630 nM, the sigmoidal curve of the 
H69 falls below that of the H69AR until about 8 µM where the curves converge. This 
means that between 630 nM and 8 µM, the drug kills relatively more H69 than H69AR, 
and after 8 µM, the drug shows similar efficacy on both cell lines.  
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Figure 6. Dose-dependent cytotoxicity on SCLC cells from a 0.5-degree serial dilution of 
(a). Alexidine HCl (S4302) with starting concentration of 15 μM. (b). Ouabain (S4016) 
with starting concentration of 250 nM. (c). Cetrimonium bromide (S4242) with starting 
concentration of 25 μM. Cells were incubated for 96hrs, and viability was assessed by MTT 
assay. Drug effect was normalized with 0.15%, 0.05%, and 0.25% DMSO for alexidine 
HCl, ouabain, and cetrimonium bromide, respectively. Error bars represent standard errors 
of the mean of two experiments done in triplicate. 
 
 
Drug code Drug name Drug class H69 (Mean ± 
SEM)/uM 
H69AR (Mean ± 
SEM)/uM 
S4302 Alexidine Antimicrobial (1.1200 ± 0.0072) (1.1000 ± 0.0080) 
S4016 Ouabain Cardiac 
glycoside 
(1.100 ± 0.020) (2.000 ± 0.031) 
S4242 Cetrimonium 
bromide 
Surfactant (7.900 ± 0.053) (9.10 ± 0.83) 
Table 2: Phenotype B drugs descriptions and their IC50 values for H69 and H69AR 
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2.3.3. Phenotype C – Collateral Sensitivity 
The term collateral sensitivity is used to describe the selective cytotoxicity of the 
drugs in this phenotype towards the resistant cells. It represents the fitness cost for the 
acquisition of the multi-drug resistance phenotype which involves complex genetic and/or 
transcriptional adaptations in the resistant cells. Drugs found in this phenotype were 
erlotinib, AZD1480, pyrimethamine, and fludarabine. These drugs would be referred to as 
collateral sensitizers. H69AR is resistant to oncology anthracycline drug such as 
doxorubicin and exhibits cross-resistance towards some non-oncology drugs as seen in 
Figure 3. On the contrary, the collateral sensitizers from the initial screening consistently 
exhibited selective cytotoxicity towards H69AR as seen in Figure 8. The difference in 
percent cell viability between H69 and H69AR was very large for erlotinib and AZD1480 
as compared to fludarabine and pyrimethamine. The reason for this can be attributed to the 
mechanism of action of fludarabine and pyrimethamine. These drugs are both 
antimetabolites which bear structural resemblance (as seen in Figure 7) to nucleotide bases 
used in DNA replication. The structural resemblance to the nucleotide bases enables them 
to compete with the natural nucleotide bases and curtail DNA replication. This competitive 
mechanism would require large amount of the competitors to overcome the natural 
nucleotide bases, which is why the 15 µM used in the initial screening did not show large 
differences in cell viabilities between the H69 and H69AR. On the other hand, erlotinib 
targets epidermal growth factor receptor (EGFR) and inhibits tyrosine kinase which 
eventually reduces the growth of cancer cells (Cohen et al., 2005) whiles azd1480 inhibits 
Janus kinase which is responsible for cell signaling leading to growth and development 
(Hedvat et al., 2009). These mechanisms of action of erlotinib and azd1480 are targeted 
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and would not require large concentrations of the drugs, hence the 15 µM used in the initial 
screening was very effective. However, the reason for the selective cytotoxicity of these 
drugs towards the resistant cells with minimal cytotoxicity to the parental cell, cannot be 
explained with the data shown in Figure 8. We therefore performed further experiments to 
investigate the mechanism of the collateral sensitivity of these drugs which would be 
discussed later.  
When different concentrations of the collateral sensitizers were used to determine 
the dose-dependent cytotoxicity, pyrimethamine and fludarabine were found to exhibit 
dose-dependent cytotoxicity on both cell lines. Three parameters can be deduced from the 
graphs to explain collateral sensitivity or the selective cytotoxicity. The first and the most 
important parameter is the position of the sigmoidal curves of the two cell lines. The curve 
of the H69AR must lie below that of the H69. The second parameter is the gap between 
the two sigmoidal curves. The wider the gap, the more selective the cytotoxicity of the drug 
towards the resistant cells. The third parameter is the difference in IC50 values of the two 
cell lines. For a drug to exhibit collateral sensitivity, it should have low IC50 value for the 
resistant and high IC50 value for the parental. The difference in the IC50 values of the two 
cell lines also generate a parameter called fold resistance which is used to describe how 
potent the parental cells resist the drug compared to the resistant cells. Fold resistance is 
calculated as: H69IC50/H69ARIC50.  
As shown in Figure 9 (a), the higher the concentration of pyrimethamine, the lesser 
the percent cell viability and vice versa for both H69 and H69AR. Also, the sigmoidal 
curve of the H69AR lies further below that of the H69 until the concentration increases 
pass 32 µM. After 32 µM, the drug exhibits similar strength of cytotoxicity towards the 
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parental and the resistant cells. Some drugs are toxic to cells at higher concentrations 
regardless of acquired resistance, which is why pyrimethamine at higher concentrations 
exhibited shared toxicity on both cell lines. Considering the gap between the two curves, it 
is widest at about 4 µM, and at this concentration, only 40 percent of the resistant cells 
survived compared to about 95 percent of the parental cells. Also, the IC50 value for H69AR 
is lower than that of the H69, yielding a fold-resistant value of 5 which implies that five 
times the concentration of pyrimethamine which kills 50 percent of H69AR would be 
required to kill 50 percent of H69. All these evident the selective cytotoxicity of 
pyrimethamine.  
The next drug in this phenotype is fludarabine phosphate, a purine analog which 
works by interfering with DNA replication. It is a chemotherapy medication used in the 
treatment of leukemia and lymphoma (Chun et al, 1991). As shown in Figure 9 (b), the 
nature of the two sigmoidal curves of fludarabine phosphate signifies a dose-dependent 
cytotoxicity exhibited by the drug, the sigmoidal curve of the H69AR lies below that of the 
H69, which indicates the selective cytotoxicity of fludarabine phosphate towards H69AR. 
A fold-resistance value of 6 was obtained from the IC50 values of the two cell lines, this 
means that six times the concentration needed to kill 50 percent of H69AR, would be 
required to kill 50 percent of H69. We could also deduce the widest gap between the two 
curves at about 63 µM, at this concentration, about 75 percent of the H69AR would be 
killed compared to about 5 percent of H69 which will be killed by the same concentration. 
We also found that concentrations higher than 3 mM exhibited shared cytotoxicity on both 
cell lines as seen in the Figure 9 (b). 
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 The next drug in this phenotype is erlotinib, under the brand name Tarceva, is a 
target chemotherapy medication used to treat NSCLC and pancreatic cancer (Cohen et al., 
2005). Erlotinib targets the epidermal growth factor receptor of the cell and has been shown 
to be effective in patients with or without EGFR mutations but happens to be more effective 
in NSCLC patients with EGFR mutations (Qi et al., 2012). In this work, erlotinib exhibited 
a dose-dependent cytotoxicity towards the resistant cells only with an IC50 value of 3.5 µM 
as shown in Figure 9 (c). This dose-dependent cytotoxicity of erlotinib was not seen with 
the parental cells, these cells were highly insensitive to erlotinib to the extent that about 65 
percent of the cells survived 600 µM of the erlotinib (Figure 9 (d)). For this reason, we 
were unable to obtain a sigmoidal curve for the parental cells. A deduction was therefore 
that since 600 µM of erlotinib could not kill 50 percent of the parental cells, the IC50 value 
will lie somewhere above 600 µM. This yields a very high fold-resistance value which is 
greater than 170. As mentioned earlier, erlotinib has been reported to be more effective in 
NSCLC patients with EGFR mutations. The H69 cells used in this work do not have 
mutated EGFR (EGFR-negative) and hence high resistance. On the other hand, H69AR 
also EGFR-negative but expresses MRP1, was sensitive to erlotinib. This could mean that 
the presence of the MRP1 in H69AR, would be the paramount contributing factor for the 
sensitivity of the H69AR. Till date, erlotinib has not been reported to kill small cell lung 
cancer cells (H69) and the results obtained in this work proved that erlotinib is not effective 
in killing H69 cells, however, if the H69 cells acquire multi-drug resistance by expressing 
multi-drug resistant protein 1, then erlotinib will be very effective in killing them, as shown 
in Figure 9 (c).  
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The last drug in this phenotype is AZD1480, a Janus kinase inhibitor that can 
suppress growth in solid tumor. In this work, 15 µM of the drug exhibited selective 
cytotoxicity towards H69AR as shown in Figure 8. Also, the drug exhibited a dose-
dependent cytotoxicity towards H69AR but not on the H69. The cytotoxicity towards H69 
was anomalous and that made it difficult to settle on an IC50 value for H69 and to make 
comparative cytotoxicity as it was done for other three collateral sensitizers. The dose-
dependent data for the AZD1480 was not shown. Since 15 µM of the drug exhibited 
selective cytotoxicity or collateral sensitivity, the drug was included in further experiments 
to investigate its mechanisms of collateral sensitivity.  
 
 





Figure 8. Viability of SCLC cells showing collateral sensitivity in H69AR on exposure to 
15 μM drugs for 96 hours. Viability was assessed by MTT assay and drug effect was 
normalized with 0.015% DMSO. Error bars represent standard errors of the mean of two 
experiment each done in triplicate. *S denotes cell viability of H69 significantly different 


















Figure 9: Dose dependent cytotoxicity on SCLC cells from a 0.5-degree serial dilution of 
(a). Pyrimethamine with starting concentration of 50 μM for both H69 and H69AR. (b). 
Fludarabine with starting concentration of 1600 μM for both H69 and H69AR. (c). 
Erlotinib with starting concentration of 50 μM for H69AR (d). Erlotinib with starting 
concentration of 600 μM for H69. Cells were incubated for 96hrs, and viability was 
assessed by MTT assay. Drug effect was normalized with 0.05% DMSO. Error bars 
represent standard errors of the mean of two experiments done in triplicate. 
 
 Table 3. Description of collateral sensitizers and their IC50 values for H69 and H69AR     
Drug name Drug class H69 (Mean ± 
SEM)/uM 




Pyrimethamine Antimalarial (12.15 ± 0.32) (2.4 ± 0.027) 5 
Fludarabine Oncology (128.4 ± 2.4) (20.7 ± 2.9) 6 
Erlotinib Oncology > (600 ± 1.35) (3.52 ± 0.411) > 170 




INVESTIGATE THE CYTOTOXIC MECHANISM OF NON-ONCOLOGY DRUGS ON 
BOTH H69 AND H69AR 
 
3.1. Introduction 
Three non-oncology drugs: alexidine HCl, ouabain and cetrimonium bromide from 
the previous experiment were found to exhibit shared cytotoxicity which is dose dependent. 
Alexidine is an alkyl bis(biguanide) antiseptic which has been used in mouthwashes to 
eliminate plaque forming microorganisms (Zorko & Jerala, 2008). It binds to 
lipopolysaccharide and lipoteichoic acid and inhibits fungal phospholipase B (Coburn et 
al., 1978). Alexidine also inhibits the mitochondrial phosphatase PTPMT1 and induces 
apoptosis in cancer cell lines. Ouabain also known as g-strophanthin, is a plant derived 
toxic substance that was traditionally used as an arrow poison in eastern Africa for both 
hunting and warfare. Ouabain is a cardiac glycoside and in lower doses, can be used 
medically to treat hypotension and some arrhythmias (Wang et al., 2004). It acts by 
inhibiting the Na/K-ATPase, also known as the sodium-potassium ion pump. Cetrimonium 
bromide (CTAB) is a quaternary ammonium surfactant. It is also an effective antiseptic 
agent against bacteria and fungi. CTAB exhibits anticancer cytotoxicity against several 
HNC (head and neck cancer) cell lines with minimal effects on normal fibroblasts, a 
selectivity that exploits cancer-specific metabolic aberrations (Ito et al., 2009). 
In this investigation, annexin V/7-aminoactinomycin D (7-AAD) apoptosis assay 
was employed to find the mode of cell death induced by these three non-oncology drugs. 
25 
 
In chemotherapeutics, drugs that induce apoptosis are preferred to those that do not. This 
is because it is easier to comprehend the mechanisms of these drugs to help in the 
manufacturing of novel drugs. Apoptosis is a programmed cell death mechanism that many 
organisms utilize to selectively eliminate cells which show either deleterious reactivities to 
the host or which have not received a full complement of activation or survival signals. 
Most chemotherapeutic and targeted cancer therapies kill tumor cells through the 
generation of pro-death signaling that initiates the intrinsic apoptotic pathway of 
programmed cell death. The point of no return in the apoptotic cascade is mitochondrial 
outer membrane permeabilization (MOMP); once it has occurred, it leads to the formation 
of an apoptosome which facilitates caspase activation and subsequently triggers the other 
hallmarks of apoptotic cell death. Annexin V and 7-AAD fluorochromes can be used to 
investigate early and late apoptosis. Annexin V mature molecule is a 320 amino-acid 
residue, folded into a planar cyclic arrangement of four repeats with each repeat composed 
of five alpha-helical segments (Demchenko, 2013). it has selective affinity for negatively 
charged phospholipids. Under defined salt and calcium concentrations, Annexin V is 
predisposed to bind phosphatidylserine over most other phospholipid (Demchenko, 2013). 
Phosphatidyl serine and phosphatidyl ethanolamine are the two major lipid components 
found on the inner side of the lipid bilayer. An alteration in the membrane asymmetry as 
part of the physiological changes seen in apoptotic cells will result into exposure of the 
phosphatidyl serine to the exterior. These are thought to be early events during the 
apoptotic process that culminate in cell death. Annexin V can selectively bind to cells with 
a compromised membrane phospholipid asymmetry and this property has been exploited 
to identify populations of cells undergoing apoptosis. During programmed cell death, loss 
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of cell membrane integrity is a very late event usually preceded by the destructive action 
of endogenous cellular enzymes (Kanduc et al., 2002; Leist & Nicotera, 1997). The 
fluorescent DNA intercalator, 7-AAD, would enter a nucleus with compromised nuclear 
membrane and bind to DNA (Holm et al., 1998). The spectral shifts of these two 
fluorochromes upon binding to their respective targets make them suitable to be employed 
in flow cytometry to detect early and late apoptosis induced by apoptotic agents. 
 
3.2. Apoptosis Assay 
3.2.1. Materials and Methods 
3.2.1.1. Chemicals 
FDA-approved drugs (Alexidine HCl, Ouabain, Cetrimonium bromide) were 
procured from Selleckchem (Houston, TX), APC-Annexin V, Annexin binding buffer and 
7-AAD were procured from BD Biosciences (San Jose, CA) and sodium dodecyl sulfate 
was procured from Sigma-Aldrich (St. Louis, MO). 
3.2.1.2. Cell lines and cell culture 
H69 cells were procured from ATCC (Manassas, VA). H69 and H69AR cell lines 
were cultured in RPMI 1640 (ATCC) media supplemented with 10% fetal bovine serum.  
Cells were grown in a humidified incubator maintaining 5% CO2 at 37 °C. 
3.2.1.3. Annexin V/7-AAD apoptosis assay 
Apoptosis stages were analyzed with annexin V and 7-AAD fluorometric assay. 
This assay can also account for cells that undergo necrosis. 250,000 cells in 100 μL RPMI 
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1640 media are seeded in 6-well plate. Plate is incubated at 37oC for 24 hrs. The next day, 
cells are treated with 15 μM of drugs and incubated at 37oC for 48 hrs. After the incubation 
period, cells are removed and centrifuged at 300 rpm for 5mins. Supernatant is discarded 
and the pellet is redissolved in phosphate buffer saline (PBS) for a second round of 
centrifugation to wash debris and residual media from cells. Annexin V (1x) binding buffer 
is added to cells prior to the addition of annexin V and 7-AAD. Cell plate is covered with 
foil to provide a dark environment for about 30mins incubation. Fluorometric reading is 
done with BD Accuri flow cytometry reader. 
 
3.3. Results and Discussion 
One of the early morphological changes in cells undergoing apoptosis is the 
exposure of phosphatidyl serine on the surface of the cell membrane. This is followed by 
the later stage of apoptosis, where the nuclear membrane becomes compromised, allowing 
the entry of substances. Nuclear components begin to disintegrate together with other 
organelles after the late phase and form apoptotic bodies. These apoptotic bodies are 
engulfed by macrophages in a process known as efferocytosis which clears dead and dying 
cells to promote homeostasis and marks the completion of apoptosis. However, an 
alternative and largely underestimated outcome of apoptosis is secondary necrosis, an 
autolytic process of cell disintegration with release of cell components that occurs when 
there is no intervention of macrophages. This is mostly seen in tissue culture. 
This investigation employed flow cytometric analysis of cells undergoing apoptosis 
when exposed to the non-oncology drugs. Two fluorescent conjugated dyes annexin V-
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APC and 7-AAD, were used to monitor the stages of apoptosis of the cells. The flow 
cytometer then sorts cells into four quadrants. The first quadrant is Lower left (LL) 
quadrant which has cells that are negative for both dyes. Cells in this quadrant are not 
undergoing apoptosis and therefore have their cell membrane and nuclear membrane intact 
and hence negative for both dyes. Cells present in the LL quadrant are live cells. The second 
quadrant is the Lower right quadrant, cells in this quadrant are positive for annexin V but 
negative for 7-AAD. Cells here have their phosphatidyl serine exposed but an intact nuclear 
membrane. Annexin V can therefore bind to the exposed phosphatidyl serine and cause 
fluorescence. These cells are thought to be in the early phase of apoptosis. The third 
quadrant is the upper right (UR) quadrant which has cells that are positive for both dyes. 
This designates the late phase of apoptosis because both the cell and nuclear membranes 
are compromised and hence their positive response to both dyes. The last quadrant is the 
upper left (UL) quadrant which may contain disintegrated cells from apoptosis (secondary 
necrosis) or cells that underwent necrosis (primary necrosis). These cells are negative for 
annexin V but positive for 7-AAD. 
In Figure 10 showing alexidine, a significant difference (p < 0.005) was seen in the 
percentages between drug-treated cells and the control at the early and late phases. More 
cells were seen in the lower right quadrant or the early phase than the late phase for both 
H69 and H69AR. Alexidine has been reported to induce apoptosis in some other cancer 
cell lines (Zorko et al., 2008). In this investigation, alexidine HCl has again been shown to 
induce apoptosis in small cell lung cancer cells (H69 and H69AR). 
The results from ouabain in Figure 11(a) showed no H69 cells in the lower right 
quadrant or early phase and upper right quadrant or late phase. But there is quite a 
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significant number (p < 0.005) of cells seen in the upper left quadrant. As mentioned 
earlier, cells in the upper left quadrant may represent debris from apoptosis (secondary 
necrosis) or actual necrosis. In the case of ouabain effect on H69, where no cells are found 
in the quadrants that represent apoptosis, thus the lower right and upper right, ouabain 
effect is said to be necrotic (primary or actual necrosis). With H69AR, ouabain is thought 
to induce apoptosis, as shown in Figure 11(b), there is a significant difference (p < 0.05) 
between the control and the drug-treated cells. Ouabain according to these results, is 
therefore necrotic to H69, and apoptotic to H69AR. One possible explanation to this could 
stem from the poisonous nature of ouabain. Ouabain at high concentrations such as the one 
used in this experiment is toxic to cells. H69AR which happens to overexpress MRP1 that 
defends the cell against toxic xenobiotics, will pump the drug out of the cell. This pumping 
mechanism could lead to the cells dying in a programmed manner. H69 on the other hand, 
does not express MRP1 for defense and will therefore succumb to the toxic action of 
ouabain.  
The results from cetrimonium bromide according to Figure 12 indicate apoptosis 
induction by the drug in both H69 and H69AR. Significant number (p < 0.05) of cells were 
seen in the lower right quadrants or the early phases for both cell lines. Also, Figure 12(c) 
showed a significant number (p < 0.05) of cells in the upper left quadrant which represent 
debris or disintegrated apoptotic bodies from the final stage of apoptosis (secondary 
necrosis). This is not uncommon in tissue culture due to the absence of macrophages to 





Figure 10. Flow cytometric analysis of the apoptotic effect of Alexidine HCl on (a). H69 
and (b). H69AR apoptosis. Cells were treated with 15 μM Alexidine HCl and incubated for 
48hrs. Some of the cells were treated with 0.15% DMSO as a control. Annexin V-APC and 
7-AAD dyes were used to detect cells undergoing apoptosis. 10,000 cells were counted. 
(c). and (d). show the percentages of H69 and H69AR cells respectively in the different 
stages of apoptosis. Error bars represent standard errors of the mean of two experiment 
each done in triplicate. *s and *ns denote significant difference (p < 0.05) and non-
significant difference (p > 0.05) respectively between drug treated cells and the control, 








Figure 11. Flow cytometric analysis of Ouabain. (a). H69 (b). H69AR apoptosis. Cells 
were treated with 15 μM Ouabain and incubated for 48hrs. Some of the cells were treated 
with 0.15% DMSO as a control. Annexin V-APC and 7-AAD dyes were used to detect cells 
undergoing apoptosis. (c). and (d). show the percentages of H69 and H69AR cells 
respectively in the different stages of apoptosis. Error bars represent standard errors of the 
mean of two experiment each done in triplicate. *s and *ns denote significant difference (p 
< 0.05) and non-significant difference (p > 0.05) respectively between drug treated cells 





Figure 12. Flow cytometric analysis of Cetrimonium bromide. (a). H69 and (b). H69AR 
apoptosis. Cells were treated with 15 μM Cetrimonium bromide and incubated for 48hrs. 
Cells treated with 0.15% DMSO is used as a control. Annexin V-APC and 7-AAD dyes 
were used to detect cells undergoing apoptosis. (c). and (d). show the percentages of H69 
and H69AR cells respectively in the different stages of apoptosis. Error bars represent 
standard errors of the mean of two experiment each done in triplicate. *s and *ns denote 
significant difference (p < 0.05) and non-significant (p > 0.05) between drug treated cells 







INVESTIGATING THE MECHANISM AND TARGETS OF COLLATERAL 
SENSITIVITY INDUCED BY FDA-APPROVED DRUGS ON MRP1-
OVEREXPRESSED CELLS 
 
4.1.  Introduction 
Although MRP1 can transport a broad spectrum of drugs out of the cell leading to 
chemotherapy failure, certain drugs or agents can expose the Achille’s heel (weakness) of 
these MRP1-overexpressed cells leading to their death. This phenomenon where certain 
agents are selectively cytotoxic towards the MRP1-overexpressed cells (resistant cells) is 
referred to as collateral sensitivity. Collateral sensitivity (CS) is a synthetic lethargy 
wherein the genetic alteration accrued while developing resistance towards one agent is 
accompanied by the development of hypersensitivity towards a second agent. The term CS 
was first described qualitatively by Szybalski and Bryson in 1952 after observation that 
drug resistant Escherichia coli displayed hypersensitivity to unrelated agents, thus 
acquiring a potential exploitable weakness because of the drug selection process. There 
have been purported findings which seem to explain the complex mechanism of collateral 
sensitivity, each supported by limited experimental evidence. These hypotheses attempt to 
explain CS by the ability of CS agents to: 1. produce reactive oxygen species (ROS) via 
futile hydrolysis of ATP (Lövborg et al., 2006), 2. exploit energetic sensitivities (Cole & 
Deeley, 2006), and 3. extrude endogenous substrate which are essential for cell survival 
(Cole & Deeley, 2006). These afore-mentioned putative mechanisms of collateral 
34 
 
sensitivity have been summarized in Figure 13 below. According to these putative 
mechanisms, when a collateral sensitizer for example drug A enters a MRP1-overexpressed 
cell, it may trigger inflammation and/or undergo phase II metabolism. It is known that 
MRP1-overexpressed cells must conjugate certain drugs in phase II detoxification 
metabolism aided by glutathione S transferase (GST) with reduced glutathione (GSH) for 
their transport (Cole & Deeley, 2006). Glutathione is a tripeptide antioxidant made up of 
the amino acid glycine, cysteine, and glutamic acid. Glutathione is the most abundant 
antioxidant among the class of thiols found in the body and it alleviates oxidative stress 
caused by reactive oxygen species (ROS) such as hydrogen peroxide, superoxide, hydroxyl 
radical, and singlet oxygen, which are generated during mitochondrial oxidative 
metabolism as well as in cellular response to xenobiotics, cytokines, and bacterial invasion. 
In Figure 13 below, the GSH conjugated collateral sensitizer (A-GSH) is being transported 
out of the cell by the MRP1 which utilizes the hydrolysis of ATP (Adenosine triphosphate). 
On the other hand, when the collateral sensitizer triggers inflammation, leukotriene C4 
(LTC4) which is a pro-inflammatory mediator will be synthesized by the addition of GSH 
to leukotriene A4 (LTA4) by LTC4 synthase (Jakobsson et al., 1996). The LTC4-GSH 
formed is an endogenous substrate of the MRP1, which is transported out of the cell by the 
MRP1 by utilizing the hydrolysis of ATP. These two mechanisms deplete glutathione as 
well as the energy bank (ATP) of the cell and generate oxygen radicals. To summarize this, 
drugs which happen to induce collateral sensitivity on H69AR cells could be involved in 
depletion of glutathione either through phase II metabolism or cause an inflammation by 





Figure 13. Putative mechanism of collateral sensitivity. 
 
In the initial screening of the FDA-approved drugs, H69AR showed 
hypersensitivity towards erlotinib, AZD1480, fludarabine, and pyrimethamine. Thus, these 
drugs exhibited collateral sensitivity towards H69AR. This collateral sensitivity could 
result from the overexpression of MRP1. As mentioned earlier, MRP1-overexpressed cells 
respond to certain xenobiotics and inflammation by pumping out glutathione, which is vital 
for the cell’s defense against oxidative stress. This can result into apoptosis of the cell. In 
this investigation, three mechanistic approaches would be used to validate the previously 
described putative mechanisms of collateral sensitivity, and to find the targets of the 
cytotoxicity induced by these drugs. 
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The first approach is to employ MRP1 dependent assay where the efflux activity of 
the MRP1 will be halted prior to addition of the collateral sensitizers. Stopping the efflux 
activity means that considerable amount of GSH may always be present in the cytosol to 
alleviate oxidative stress and hence survival of the cell. 
In the second approach, caspase dependent assay would be used to investigate the 
mechanism of cytotoxicity. Apoptosis and necroptosis are both caspase-dependent 
programmed cell death. There are 13 known mammalian caspases classified either as 
initiator or executor of apoptosis. Caspases 8, 9 and 10 are examples of initiator caspases 
whiles 3, 6 and 7 are examples of effector caspases. Inhibition of these caspases, especially 
the initiator caspases will prevent programmed cell death. In a caspase dependent assay, 
addition of pan caspase inhibitor Q-VD-Oph irreversibly inhibits caspase 1,3,8 and 9 
(Keoni & Brown, 2015). Intrinsic apoptotic pathway is initiated through caspase 9 while 
extrinsic pathway is initiated through caspase 8. This means that Q-VD-Oph can inhibit 
both intrinsic and extrinsic pathways leading to apoptosis. A collateral sensitizer that 
induces apoptosis through caspases, will show an increase in cell viability when the 
caspases are inhibited and vice versa. Most oncology drugs trigger apoptosis via production 
of ROS. The damage done to proteins, lipid membranes, nucleic acids and other organelles 
by ROS could lead to activation of programmed cell death by invoking caspases. 
Irreversible inhibition of caspases in both the intrinsic and extrinsic pathways should show 
a significant increase in cell viability when cells are treated with apoptotic agents. 
The last approach would employ a fluorometric total thiol-depletion assay where 
total thiols in the cytosol will be measured after addition of collateral sensitizers. The 
fluorogenic dye dibromobimane, is widely used to detect various thiol-containing 
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biomolecules such as glutathione in cells. It is a unique fluorogenic cross-linking reagent 
for thiols because it is unlikely to fluoresce until both of its alkylating groups have reacted 
(Moore et al., 1995). Glutathione happens to be the most abundant of the total thiols in 
cells. Depletion of total thiols encompasses depletion of glutathione which could be used 
as a marker of collateral sensitivity. 
 
4.2.  MRP1 Dependent Collateral Sensitivity Assay 
4.2.1. Materials and Methods 
4.2.1.1. Chemicals 
FDA-approved drugs (Erlotinib, azd1480, Fludarabine, pyrimethamine) were 
procured from Selleckchem (Houston, TX). Thiazolyl blue tetrazolium bromide (MTT) 
and Q-VD-Oph were procured from ApexBio (Houston, TX). MK-571, reversan and 
sodium dodecyl sulfate were procured from Sigma-Aldrich (St. Louis, MO). 
4.2.1.2. Cell lines and cell culture 
H69 and H69AR cells were procured from ATCC (Manassas, VA). H69 cell lines were 
cultured in RPMI 1640 (ATCC) media supplemented with 10% fetal bovine serum. H69AR 
cells were challenged monthly with 0.8 µM doxorubicin and cultured drug-free for one 






4.2.1.3. Cytotoxicity assay 
Cell sensitivity to drugs was analyzed using the MTT colorimetric assay. 250,000 
cells in 100 ul RPMI 1640 media are seeded in 96-well plate (CellBIND®, Corning). Plate 
is incubated at 37oC for 24 hrs. The next day, cells were treated with 25 µM of MK-571 or 
5 μM of reversan (potent MRP1 inhibitors) for 90 mins in incubation before 15 µM of 
collateral sensitivity drugs were added and incubated for 96 hrs. DMSO concentration was 
maintained at 0.035%. At the end of the incubation period, 100 µL of culture medium was 
carefully removed and cells were treated with MTT (0.5 mg/mL) for 4 hrs. The formazan 
crystals were dissolved by the addition of 120 ul of 15% SDS containing 0.01%v/v HCl, 
and absorbance at 570 nm was recorded using a Hidex Sense Beta Plus plate reader (Turku, 
Finland). 
 
4.3.  Results and Discussion 
As previously stated, MRP1 effluxes conventional cytotoxic oncology and non-
oncology agents. This efflux action of the MRP1-overexpressed cells may play a role in 
the collateral sensitivity induced by certain agents. In this investigation, two potent MRP1 
inhibitors MK-571 and Reversan, were used to inhibit MRP1 prior to the addition of 
collateral sensitizers. MK-571 is a selective, orally active leukotriene D4/E4 receptor 
antagonist for the treatment of bronchoconstriction (Manning et al., 1990, Amirey et at., 
1991). Reversan is one of the most potent pyrazolopyrimidine when used in combination 
with either vincristine or etoposide to treat neuroblastoma in vivo (Burkhart et al., 2008). 
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Recall from Figure 13, transport activity of the MRP1 can cause depletion of GSH 
and ATP. By stopping the transport activity of the MRP1 with a potent inhibitor such as 
MK-571 or reversan, the transport of GSH and energy utilization would be eliminated, and 
cells would now have enough GSH to mitigate oxidative stress and hence cell survival. In 
this investigation, inhibition of MRP1 by MK-571 reversed the collateral sensitivity 
induced by erlotinib. In other words, more cells survived (p < 0.05) when MK-571 and 
erlotinib (indicated as erlMK on the bar graph) were added to cells as compared to adding 
only erlotinib (indicated as erl on the bar graph) to cells as shown in Figure 14(a). This 
collateral sensitivity reversal did not occur with the remaining three drugs since there were 
no significant differences (p > 0.05) in cell viability between inhibited and non-inhibited 
MRP1. On the other hand, inhibiting with reversan showed that the collateral sensitivities 
of all four drugs were dependent on the MRP1. This is because there is significant 
difference (p < 0.05) in cell viabilities between inhibited and non-inhibited MRP1 for all 
four drugs as shown in Figure 14 (b). However, the differences seen with AZD 1480 and 
fludarabine are relatively smaller than those of erlotinib and pyrimethamine. Transport of 
drugs by MRP1 out of the cell could take either one of these forms, transport of a free drug 
or transport of a drug with GSH. All these forms of transport out of the cell may require 
different forms of binding to the MRP1 (Gottesman et al., 2009), these different forms of 
binding could arise to different inhibitory mechanisms. In Figure 14 (b), reversan probed 
more drugs than MK-571 which is a clear indication that both inhibitors have different 
inhibitory mechanisms, which could be attributed to the different forms of binding of the 
MRP1. The collateral sensitivity of erlotinib disappeared with the inhibition by both MK-
571 and reversan, meaning that the collateral sensitivity induced by erlotinib is responsive 
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to the different forms of inhibition by MK-571 and reversan. Inferring from Figure 14(b), 
the collateral sensitivity of azd1480 and fludarabine to some extent (even though not as 
prominent as seen in erlotinib and pyrimethamine) is dependent on the efflux activity of 
the MRP1 since there was significant difference (p < 0.05) in the percent viabilities of the 




Figure 14. Viability of H69AR cells showing the effect of inhibiting MRP1 prior to the 
addition of collateral sensitizers. Cells were treated with (a) 25 μM of MK-571, (b) 5 μM 
of reversan (both of which are MRP1 inhibitors) and incubated for 90 mins before addition 
of 15 μM drugs for 96hrs (for MK-treated cells) and 72hrs (for reversan-treated cells). 
Viability was assessed by MTT assay and drug effect was normalized with 0.035% DMSO. 
Error bars represent standard errors of the mean of two experiments each done in triplicate. 
*s and *ns denote significant and non-significant difference respectively with p < 0.05 for 






4.4. Caspase Dependent Collateral Sensitivity Assay 
4.4.1. Materials and Methods 
4.4.1.1. Chemicals 
FDA-approved drugs (Erlotinib, Azd1480, Fludarabine and Pyrimethamine) were 
procured from Selleckchem (Houston, TX). Thiazolyl blue tetrazolium bromide (MTT) 
and Q-VD-Oph were procured from ApexBio (Houston, TX), APC-Annexin V, Annexin 
binding buffer and 7-AAD procured from BD Biosciences (San Jose, CA) and sodium 
dodecyl sulfate was procured from Sigma-Aldrich (St. Louis, MO). 
4.4.1.2. Cell lines and cell culture 
H69 and H69AR cells were procured from ATCC (Manassas, VA). H69 cell lines 
were cultured in RPMI 1640 (ATCC) media supplemented with 10% fetal bovine serum. 
H69AR cells were challenged monthly with 0.8 µM doxorubicin and cultured drug-free for 
one week before use. Cells were grown in a humidified incubator maintaining 5% CO2 at 
37 °C. 
4.4.1.3. Cytotoxicity assay 
Cell sensitivity to drugs was analyzed using the MTT colorimetric assay. 250,000 
cells in 100 μL RPMI 1640 media are seeded in 96-well plate (CellBIND®, Corning). Plate 
is incubated at 37 oC for 24hrs. The next day, cells were treated with 25 μM of Q-VD-Oph 
(pan caspase inhibitor) and incubated for 90 min, before 15 µM of non-oncology drugs 
were added and incubated for 96 hrs. DMSO concentration was maintained at 0.15%. At 
the end of the incubation period, 100 ul of culture medium was carefully removed and cells 
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were treated with MTT (0.5 mg/mL) for 4 hrs. The formazan crystals were dissolved by 
the addition of 120 µL 15% SDS containing 0.01%v/v HCl and absorbance at 570 nm were 
recorded using a Hidex Sense Beta Plus plate reader (Turku, Finland). 
 
4.5.  Results and Discussion 
Programmed cell death such as apoptosis and necroptosis involve procaspase 
(cysteine-dependent aspartate-directed proteases) activation. Two major forms of caspases 
exist for apoptosis to take place, the initiator caspases and the effector or executioner 
caspases. Inhibition of caspases, more importantly the initiator caspases, could prevent 
apoptosis from taking place. In this investigation, a potent pan caspase inhibitor Q-VD-
Oph which has being found to inhibit caspase 1, 3, 8, and 9 is added prior to the addition 
of collateral sensitivity drugs. Agents that induce caspase-dependent apoptosis do that 
through a death receptor pathway (extrinsic pathway) or intrinsic pathway as shown in 




Figure 15. Inhibitory effect of a caspase inhibitor (Q-VD-Oph) on extrinsic and intrinsic 
pathways leading to apoptosis. 
 
When conditions in the extracellular environment determine that a cell must die, 
extrinsic pathway will occur. For the extrinsic pathway, death ligands, such as FasL, bind 
to the death receptor Fas. This receptor-ligand binding, together with Fas-associated death 
domain (FADD), generate death-inducing signaling complex (DISC), which in turn 
recruits and assembles initiator caspase-8. This caspase activates the effector caspase-3 and 
7, resulting in nuclear protein cleavage and apoptosis. For the intrinsic pathway, stress in a 
form of DNA damage induces p53 to activate Bax (B-cell lymphoma associated protein x) 
and Bak (B-cell lymphoma associated protein k), or bid is converted to tbid by caspase 8 
which activates Bax and Bak. Bax and Bak act on mitochondria and cause the release of 
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cytochrome C which then combines with Apaf1 (apoptosis activating factor 1) and in turn 
activates pro-caspase 9 to caspase 9. Caspase 9 then activates effector caspase 3 and 7 
resulting in apoptosis. Both extrinsic and intrinsic pathways converge at the effector 
caspases which initiate the actual apoptosis process. 
The caspase inhibitor (CI), (Q-VD-Oph), used in this experiment inhibits the 
intrinsic initiator caspase-9, extrinsic initiator caspase-8 and the effector or the executioner 
caspase-3 as shown Figure 15. This inhibitory function of Q-VD-Oph is such that both 
intrinsic and extrinsic pathways leading to apoptosis would be blocked prior to the addition 
of an apoptotic agent. 
As shown in Figure 16, a significant difference (p < 0.05) in cell viability between 
inhibited and non-inhibited cells was seen with erlotinib and AZD 1480. This significant 
difference is evidence of their caspase dependent collateral sensitivity. Erlotinib has been 
found to inhibit EGFR, and AZD 1480 has also been found to inhibit Janus kinase. The 
functions of these drugs result in the compromise of downstream signaling that leads to the 
growth or development of cells. Cells are programmed to die when their growth or 
development is compromised. In this experiment, the pro-caspase activation pathways that 
were induced by erlotinib and AZD1480 were blocked by the pan caspase inhibitor Q-VD-
Oph hence the significant differences. It is therefore evident in this investigation that the 
cytotoxicity of erlotinib and AZD1480 depend on caspase. Pyrimethamine and fludarabine 
on the other hand did not show significant difference (p > 0.05) in cell viability between 
inhibited and non-inhibited cells. Both drugs are antimetabolite and indirectly affect ATP 
production. Cells can pull energy in the form of ATP from different metabolic pathways. 




Figure 16. Viability of H69AR cells showing the effect of inhibiting pan caspase prior to 
the addition of collateral sensitivity drugs. Cells were treated with 25 µM Q-VD-Oph (a 
pan caspase inhibitor (CI)) and incubated for 90 mins before addition of 15 μM drugs for 
4 hours. Viability was assessed by MTT assay and drug effect was normalized with 0.015% 
DMSO. Error bars represent standard errors of the mean of two experiments each done in 
triplicate. *s and *ns denote significant and non-significant difference respectively with p 
< 0.05 for *s and p > 0.05 for *ns. 
 
4.6.  Total Thiol (Glutathione) Depletion 
4.6.1. Materials and Methods 
4.6.1.1. Chemicals 
FDA-approved drugs (Erlotinib, azd1480, Fludarabine, pyrimethamine) were 
procured from Selleckchem (Houston, TX). Dibromobimane, and N-acetylcysteine (NAC) 
were procured from ApexBio (Houston, TX).  Sodium dodecyl sulfate was procured from 




4.6.1.2. Cell lines and cell culture 
H69 and H69AR cells were procured from ATCC (Manassas, VA). H69 cell lines 
were cultured in RPMI 1640 (ATCC) media supplemented with 10% fetal bovine serum. 
H69AR cells were challenged monthly with 0.8 µM doxorubicin and cultured drug-free for 
one week before use. Cells were grown in a humidified incubator maintaining 5% CO2 at 
37 °C. 
4.6.1.3. Thiol depletion assay 
Total thiol depletion by drugs was analyzed using dibromobimane fluorescence 
assay. 250,000 cells in 100 µL RPMI 1640 media are seeded in 96-well plate (NUNC®). 
Plate is incubated at 37 oC for 24hrs. The next day, cells were treated with 50 µM of N-
acetylcysteine (NAC) or 50 µM L-buthionine sulfoximine (BSO) for 48 hours in 
incubation, before 30 µM of collateral sensitivity drugs were added and incubated for 12 
hours. DMSO concentration was maintained at 0.035%. A 20 uM dibromobimane was 
added to cells and incubated for an hour. Fluorescence reading was done with cytation3 
reader at excitation and emission wavelengths of 393 nm and 490 nm, respectively. 
 
4.7. Results and Discussion  
GSH depletion as discussed earlier, is anticipated to result from the transport of a 
drug out of the cell or production of the inflammatory mediator LTC4. In this investigation, 
N-acetylcysteine (NAC) is first added to cells to stimulate GSH production above basal 
levels before addition of collateral sensitizers. Cells without NAC were used as control to 
monitor basal GSH production. Dibromobimane is then added to react with the thiols left 
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after addition of collateral sensitizers. The reaction of bromobimanes mostly occurs by SN2 
displacement of bromide ion by a thiolate anion from cysteine residue as shown below. 
The oxidized complex formed can now fluoresce with excitation and emission wavelengths 
in the uv-vis range. Dibromobimane will not fluoresce until both akylating groups have 
reacted. This means that two molecules of thiol-containing compounds (GSH) are required 
to cause dibromobimane to fluoresce. 
 
Figure 17. SN2 displacement of bromide ions on dibromobimane by thiolate anion on 
cysteine residues. 
In the cell, γ-glutamylcysteine synthetase, a key enzyme in glutathione biosynthesis 
converts NAC into glutathione which led to an increase in relative fluorescence unit (RFU) 
as shown in Figure 18. L-buthionine sulfoximine (BSO), also used in this experiment, 
induces experimental glutathione deficiency by inhibiting γ-glutamylcysteine synthetase 
(Akan et al., 2005). BSO added with NAC to the cells at the same time was able to inhibit 
this enzyme and therefore showed a significant decrease (p < 0.05) in total thiol (GSH) 
hence a lower RFU (Figure 18). Vincristine which is used to treat leukemia and other types 
of cancers, including small cell lung cancer, has been reported to exhibit a co-transportation 
with GSH by MRP1 (Loe et al., 1998; The American Society of Health-System 
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Pharmacists, n.d.). In this work, vincristine showed a significant decrease (p < 0.05) in 
RFU corresponding to depletion in total thiols (GSH).  
Erlotinib and AZD1480 also depleted total thiols (GSH) significantly (p < 0.005) 
showing lower RFU values as seen in Figure 18. The depletion caused by these two drugs 
reveals the role of GSH in the collateral sensitivity induced by the drugs.  
Fludarabine phosphate and pyrimethamine did not show significant decrease (p > 
0.05) in RFU as seen in Figure 18. Both fludarabine and pyrimethamine are antimetabolite 
which can exploit the energetic sensitivity of MRP1-overexpressed cells such as H69AR. 
Although both drugs did not deplete GSH, they could induce their collateral sensitivity 
through exploitation of the energetic sensitivity of these cells leading to their death. 
 
Figure 18. Depletion of total thiols induced by collateral sensitivity drugs. Cells were 
treated with 50 μM NAC and incubated for 48hrs before addition of 30 μM drugs for 12 
hours. Vincristine and BSO are used as control. Cells were treated with dibromobimane 
dye, and fluorescence were taken at excitation and emission wavelength of 393 nm and 
490 nm, respectively. Error bars represent standard errors of the mean of two experiments 
each done in triplicate. *s and *ns denote significant and non-significant difference from 





SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS 
 
5.1 Summary 
FDA-approved and clinical trial drugs were screened for their cytotoxicity towards 
small cell lung cancer cells (H69 and H69AR) using MTT cytotoxicity assay. H69AR 
happens to be the resistant form of the H69, with overexpression of multidrug resistance 
protein 1 (MRP1). After the screening, drugs were grouped based on their relative cytotoxic 
effect on both cell lines. The first group called the “resistance”, showed selective toxicity 
towards H69 (the parental cell line), but did not show significant toxicity towards H69AR 
(the resistance). The second group called “shared cytotoxicity”, showed almost equal 
toxicity towards both cell lines with cell viability percentage less than 30. Drugs in this 
group were mostly non-oncology drugs. The last group called “collateral sensitivity” 
showed selective toxicity towards the resistant cell line (H69AR). Per the goal of this work, 
which is to lend addendum to cancer chemotherapy, further experiments were performed 
to investigate the mechanism of the cytotoxicity of drugs in the last two groups. Further 
experiments started with finding the half maximal inhibitory concentration of these drugs 
or what is commonly referred to as IC50 in a dose-dependent manner using MTT 
cytotoxicity assay.  
The mechanism of the cytotoxicity of the non-oncology drugs was investigated by 
employing annexin V and 7-AAD fluorometric apoptosis assay to find out if the 
cytotoxicity of these drugs is in a programmed manner.  
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Several experiments were performed to investigate the mechanism of the 
cytotoxicity of collateral sensitivity drugs. These include: 
1. Finding whether the collateral sensitivity of these drugs is dependent on the 
pumping action of the MRP1, by inhibiting the MRP1 in MTT cytotoxicity assay. 
2. Finding whether the cytotoxicity of these drugs is programmed, by employing 
caspase dependent assay. 
3. Finding whether these collateral sensitivity drugs deplete glutathione in the cell.  
Drugs in the first group did not fit into the goal of this project and therefore no further 
experiment was performed with those drugs. 
 
5.2. Conclusions 
The two groups “shared cytotoxicity” and “collateral sensitivity”, that were of 
interest included seven drugs. Drugs in the shared cytotoxicity group were alexidine HCl, 
ouabain, and cetrimonium bromide. All three are non-oncology drugs and showed very low 
IC50 values for both H69 and H69AR. These low IC50 values inform high potency in killing 
both H69 and H69AR. The cytotoxicity of these drugs was also found to be concentration 
dependent, thus, the higher the concentration, the greater the percentage of cell death. 
Further experiments were performed to investigate the mechanisms of cell death induced 
by these drugs. Employing the traditional flow cytometry technique for apoptosis, alexidine 
HCl and cetrimonium bromide were found to induce apoptosis in both H69 and H69AR. 
Most cells were found in the early phase of apoptosis after these cells have been treated 
with 15 μM of the drugs for 48hrs. On the other hand, the effect of ouabain on H69 was 
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necrotic and on H69AR was apoptotic under the same drug concentration and conditions. 
It is worth knowing that drugs that exert their cytotoxicity in a programmed manner mostly 
would have a lead in therapeutics as compared to those that do not. Alexidine HCl and 
cetrimonium bromide would therefore be good candidates for drug repurposing in cancer 
chemotherapy. 
In the collateral-sensitivity group, four drugs, namely erlotinib, AZD1480, 
fludarabine, and pyrimethamine were found. Drugs in this group exhibited selective 
toxicity towards H69AR, which was concentration dependent in a exception of AZD1480. 
Erlotinib gave an IC50 value for H69 which is 170 times more than that of the H69AR. This 
large-fold difference informs that H69 cells are very insensitive to the drug. Pyrimethamine 
and fludarabine also gave significant differences, five and six times respectively, indicating 
their selective toxicity towards H69AR. AZD1480 at 15uM showed collateral sensitivity, 
but at varying concentrations, its toxicity towards H69 was anomalous. Thus, at one point 
it exhibited shared cytotoxicity, at another point its exhibited collateral sensitivity. This 
made it difficult for AZD1480 to be placed this category. In an experiment to investigate 
the dependency of collateral sensitivity on MRP1, MK-571 and reversan both stopped the 
collateral sensitivity induced by erlotinib. Also, the collateral sensitivity induced by 
pyrimethamine was stopped by reversan. These results conclude that the collateral 
sensitivity of erlotinib and pyrimethamine depends on the pumping action of the MRP1. 
The reversal seen in AZD1480 and fludarabine using reversan were although significant 
but too minimal to make a decisive conclusion without performing further experiments 
with different MRP1 inhibitors.  
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Drugs that induce caspase activation exhibit cytotoxicity in a programmed manner. 
In an investigation into the cytotoxicity mechanisms of the collateral-sensitivity drugs, 
erlotinib and AZD1480 showed a significant increase in cell viability percentage upon 
inhibition of caspase. Fludarabine and pyrimethamine on the other hand did not show a 
significant increase in cell viability. This concludes that erlotinib and AZD1480 exhibit 
their cytotoxicity in a programmed manner whiles fludarabine and erlotinib do not induce 
caspase activation in their cytotoxic mechanisms. 
The last part of the work featured drugs in the collateral sensitivity group. An 
investigation that was meant to reveal the correlation between GSH depletion and collateral 
sensitivity. Erlotinib and AZD1480 depleted GSH significantly. This informs that GSH 
plays a role in the collateral sensitivities of erlotinib and AZD1480. Thus, they deplete the 
cell’s antioxidant (GSH) and make cells susceptible to oxidative stress resulting into death. 
 
5.3. Recommendations 
The main goal of this project is to join the train of drug repurposing in 
chemotherapy. Drugs that were used in this project are already FDA-approved drugs and 
would be relatively easier to be accepted for drug repurposing. Erlotinib selectively kills 
H69AR in a programmed manner which involves caspase activation and depleting GSH. 
However, erlotinib cannot be effective on H69AR if the MRP1 of H69AR is blocked. 
Erlotinib would therefore be recommended to join the train of drug repurposing to treat 
small cell lung cancer cells (H69) which has overexpressed MRP1. But in situations where 
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combinatorial regimen would be applicable, erlotinib should not be combined with a drug 
that will block MRP1. 
One of the problems of cancer chemotherapeutics is the afflictive side effects. 
Therefore, a drug would be worth recommending if it is a non-oncology drug and has 
cytotoxicity potential on cancer cells. Alexidine HCl, ouabain, cetrimonium bromide, and 
pyrimethamine used in this work are non-oncology drugs and were cytotoxic to H69 and/or 
H69AR. Playing a role of surfactant, cetrimonium bromide could be used in a palliative 
procedure for lung cancer patients with breathing difficulties. Pyrimethamine, a non-
oncology antimetabolite, would be recommended for two reasons: 1). It would possess 
little side effect as a non-oncology drug. 2). It selectively kills H69AR by depending on 
the pumping mechanism of the MRP1. Again, pyrimethamine should not be combined with 
a drug that blocks MRP1, in a combinatorial regimen.  
 
5.4. Future Work 
Although the drugs used in this project were tested only on small-cell lung cancer 
cells, their cytotoxic mechanisms identified in this work could give an insight to 
mechanistic investigations on different cancer cells. Future work could focus more on the 
collateral-sensitivity mechanisms of non-oncology antimetabolite drugs on different cancer 
cells that overexpresses MRP1. Future work could also focus on screening drugs for MRP1 
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